Patents by Inventor John Simard

John Simard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment for neoplastic diseases
    Patent number: 11932688
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 19, 2024
    Assignee: XBiotech Inc.
    Inventor: John Simard
  • HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA
    Publication number: 20240034781
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 1, 2024
    Inventor: John SIMARD
  • Compositions and methods for treating and preventing staphylococcus aureus infections
    Publication number: 20240010711
    Abstract: Methods and compositions for treating a Staphylococcus aureus bloodstream infection in a human subject involve administering to the subject an antibody which specifically binds Staphylococcus aureus protein A (SpA) with a K D of less than 1×10?10 M via its Fab region paratope and is able to mediate opsonization of SpA-expressing Staphylococcus aureus bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 11, 2024
    Inventor: John Simard
  • Treatment for neoplastic diseases
    Publication number: 20230382989
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Application
    Filed: August 11, 2023
    Publication date: November 30, 2023
    Inventor: John SIMARD
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230322915
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: October 12, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • Compositions and methods for treating and preventing infections
    Patent number: 11773157
    Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: October 3, 2023
    Assignee: XBIOTECH INC.
    Inventor: John Simard
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230287103
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230287104
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230287102
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • TREATMENT OF HIDRADENITIS SUPPURATIVA
    Publication number: 20230235042
    Abstract: Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 27, 2023
    Inventors: Yanli ZHUANG, Bhaskar SRIVASTAVA, Karen KEEFE, Swaroopa PARATKAR, Bruce RANDAZZO, Emesto MUNOZ, John SIMARD
  • ARTHRITIS TREATMENT
    Publication number: 20220363750
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 17, 2022
    Inventor: John SIMARD
  • Compositions and methods for treating and preventing staphylococcus aureus infections
    Publication number: 20220251175
    Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 11, 2022
    Inventor: John Simard
  • Arthritis treatment
    Patent number: 11390672
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 19, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • ANTIBODY FORMULATION
    Publication number: 20220220196
    Abstract: Symptoms of atopic dermatitis in a human subject are reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Application
    Filed: April 22, 2020
    Publication date: July 14, 2022
    Inventor: John SIMARD
  • Compositions and methods for treating and preventing infections
    Patent number: 11370831
    Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: June 28, 2022
    Assignee: XBIOTECH INC.
    Inventor: John Simard
  • TREATMENT OF PSYCHIATRIC CONDITIONS
    Publication number: 20220062413
    Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 3, 2022
    Inventor: John SIMARD
  • Treatment of brain ischemia-reperfusion injury
    Publication number: 20220041710
    Abstract: The sequelae of cerebral ischemia-reperfusion injury are reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Application
    Filed: October 23, 2021
    Publication date: February 10, 2022
    Inventors: Giovanni Guido Camici, Luca Liberale, Peter Libby, John Simard
  • TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF
    Publication number: 20210403548
    Abstract: Administration of an antibody that, specifically binds IL-1? is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or increasing the time until restenosis occurs) in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventor: John SIMARD
  • Treatment of psychiatric conditions
    Patent number: 11191831
    Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: December 7, 2021
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • TREATMENT OF ATOPIC DERMATITIS
    Publication number: 20210238273
    Abstract: Symptoms of atopic dermatitis in a human subject are reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 5, 2021
    Inventor: John Simard